MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.oraloncology.2026.108006

Медицинская библиотека · Oral oncology · 2026

Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.

Ly Sophia, Rühle Alexander, Bratman Scott, Cho John, Hosni Ali, Hahn Ezra, Kim John, McPartlin Andrew, Ringash Jolie, O'Sullivan Brian, Tsai C Jillian, Waldron John, Goldstein David, Sanz-Garcia Enrique, Spreafico Anna, Su Jie, Tong Li, Weinreb Ilan, Huang Shao Hui, Hope Andrew

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

To report oncologic outcomes after metastasis-directed treatment (MDT) for metachronous thoracic metastases following definitive (chemo-)radiotherapy in p16-positive head and neck squamous cell carcinoma (HNSCC).

METHODS

We reviewed all p16-positive HNSCC patients who developed metachronous thoracic metastases after definitive (chemo)radiotherapy (2003-2021). Metastatic disease was further classified as oligometastatic (1-5 lesions) versus polymetastatic (>5 lesions). Overall survival (OS) was compared between those receiving metastasis-directed therapy (MDT), either surgery or radiotherapy, and those managed without MDT. We transposed the TNM8 non-small-cell-lung-cancer staging algorithm to assess differences in outcome by MDT within the "lung-type stage I-III" subset.

RESULTS

Among 1908 consecutively treated patients, 170 (9%) developed thoracic metastases, 98 (58%) of which were thorax-only. Of those, 34 (35%) had oligometastatic disease ("lung-type stage I-III"), of whom 24 received MDT: 18 surgery-only, 1 surgery + radiation, 4 radiation-only, and 1 chemoradiotherapy. Median follow-up was 2.0 years. Two-year OS was 88% with MDT versus 23% without (p < 0.001). On multivariable analysis, MDT was the only independent predictor of improved OS (adjusted hazard ratio 0.19, 95% CI 0.10-0.35, p < 0.001) adjusted for age, sex, disease site, and TNM8 stage group. Within the "lung-type stage I-III" subset, those who received MDT (n = 23/34) had higher 2-year OS versus those without MDT (87% versus 45%, p = 0.024).

CONCLUSIONS

Patients with p16-positive HNSCC and metachronous thoracic oligometastatic disease who received MDT exhibit longer OS compared to those with polymetastatic disease or those without MDT. Future trials are warranted to validate the findings and to explore the optimal treatment approach for this population.

Для цитирования: Ly Sophia, Rühle Alexander, Bratman Scott, Cho John, Hosni Ali, Hahn Ezra, Kim John, McPartlin Andrew, Ringash Jolie, O'Sullivan Brian, Tsai C Jillian, Waldron John, Goldstein David, Sanz-Garcia Enrique, Spreafico Anna, Su Jie, Tong Li, Weinreb Ilan, Huang Shao Hui, Hope Andrew. Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.. Oral oncology. 2026. DOI: 10.1016/j.oraloncology.2026.108006.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.